Citations (142)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Zhao-Jun Mo, Zhao-Feng Bi, Wei Sheng, Qi Chen, Teng Huang, Ming-Qiang Li, Xue-Lian Cui, Ya-Hui Wangjiang, Bi-Zhen Lin, Feng-Zhu Zheng, Guang Sun, Ya-Fei Li, Ya Zheng, Si-Jie Zhuang, Ying-Ying Su, Hui-Rong Pan, Shou-Jie Huang, Ting Wu, Jun Zhang & Ning-Shao Xia. (2022) Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. Human Vaccines & Immunotherapeutics 18:6.
Read now
Read now
Xiao-Juan Yu, Juan Li, Zhi-Jie Lin, Hui Zhao, Bi-Zhen Lin, You-Lin Qiao, Yue-Mei Hu, Li-Hui Wei, Rong-Cheng Li, Wei-Dan Huang, Ting Wu, Shou-Jie Huang, Chang-Gui Li, Hui-Rong Pan & Jun Zhang. (2020) Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals. Human Vaccines & Immunotherapeutics 16:7, pages 1630-1635.
Read now
Read now
Ralph-Sydney Mboumba Bouassa, Hélène Péré, Mohammad-Ali Jenabian, David Veyer, Jean-François Meye, Antoine Touzé & Laurent Bélec. (2020) Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus. Expert Review of Anti-infective Therapy 18:6, pages 579-607.
Read now
Read now
Tino F. Schwarz, Li-Min Huang, Alejandra Valencia, Falko Panzer, Cheng-Hsun Chiu, Annabelle Decreux, Sylviane Poncelet, Naveen Karkada, Nicolas Folschweiller, Lan Lin, Gary Dubin & Frank Struyf. (2019) A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Human Vaccines & Immunotherapeutics 15:7-8, pages 1970-1979.
Read now
Read now
Xue Chen, Ting Zhang, Hongyang Liu, Yaru Hao, Guoyang Liao & Xuemei Xu. (2018) Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice. Human Vaccines & Immunotherapeutics 14:8, pages 2025-2033.
Read now
Read now
Barbara Romanowski, Tino F Schwarz, Linda Ferguson, Klaus Peters, Marc Dionne, Ulrich Behre, Karin Schulze, Peter Hillemanns, Pemmaraju Suryakiran, Florence Thomas & Frank Struyf. (2016) Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Human Vaccines & Immunotherapeutics 12:1, pages 20-29.
Read now
Read now
Ting Fan Leung, Anthony Pak-Yin Liu, Fong Seng Lim, Franck Thollot, Helen May Lin Oh, Bee Wah Lee, Lars Rombo, Ngiap Chuan Tan, Roman Rouzier, Damien Friel, Benoit De Muynck, Stéphanie De Simoni, Pemmaraju Suryakiran, Marjan Hezareh, Nicolas Folschweiller, Florence Thomas & Frank Struyf. (2015) Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial. Human Vaccines & Immunotherapeutics 11:7, pages 1689-1702.
Read now
Read now
Troy J Kemp, Ken Matsui, Gloriana Shelton, Mahboobeh Safaeian & Ligia A Pinto. (2015) A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays. Human Vaccines & Immunotherapeutics 11:2, pages 337-346.
Read now
Read now
Mark H Einstein, Peter Takacs, Archana Chatterjee, Rhoda S Sperling, Nahida Chakhtoura, Mark M Blatter, Jacob Lalezari, Marie-Pierre David, Lan Lin, Frank Struyf & Gary Dubin. (2014) Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial. Human Vaccines & Immunotherapeutics 10:12, pages 3435-3445.
Read now
Read now
Mark H Einstein, Myron J Levin, Archana Chatterjee, Nahida Chakhtoura, Peter Takacs, Grégory Catteau, Francis J Dessy, Philippe Moris, Lan Lin, Frank Struyf & Gary Dubin$suffix/text()$suffix/text(). (2014) Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study. Human Vaccines & Immunotherapeutics 10:12, pages 3455-3465.
Read now
Read now
Hilary A Robbins, Tim Waterboer, Carolina Porras, Troy J Kemp, Michael Pawlita, Ana Cecilia Rodriguez, Sholom Wacholder, Paula Gonzalez, John T Schiller, Douglas R Lowy, Mark Esser, Katie Matys, Sylviane Poncelet, Rolando Herrero, Allan Hildesheim, Ligia A Pinto & Mahboobeh Safaeian. (2014) Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. Human Vaccines & Immunotherapeutics 10:10, pages 2965-2974.
Read now
Read now
Paulo S Naud, Cecilia M Roteli-Martins, Newton S De Carvalho, Julio C Teixeira, Paola C de Borba, Nervo Sanchez, Toufik Zahaf, Gregory Catteau, Brecht Geeraerts & Dominique Descamps. (2014) Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine. Human Vaccines & Immunotherapeutics 10:8, pages 2147-2162.
Read now
Read now
Fengcai Zhu, Juan Li, Yuemei Hu, Xiang Zhang, Xiaoping Yang, Hui Zhao, Junzhi Wang, Jianguo Yang, Guodong Xia, Qinyong Dai, Haiwen Tang, Pemmaraju V Suryakiran, Sanjoy K Datta, Dominique Descamps, Dan Bi & Frank Struyf. (2014) Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Human Vaccines & Immunotherapeutics 10:7, pages 1795-1806.
Read now
Read now
Barbara Romanowski, Tino F Schwarz, Linda M Ferguson, Murdo Ferguson, Klaus Peters, Marc Dionne, Karin Schulze, Brian Ramjattan, Peter Hillemanns, Ulrich Behre, Pemmaraju Suryakiran, Florence Thomas & Frank Struyf. (2014) Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination. Human Vaccines & Immunotherapeutics 10:5, pages 1155-1165.
Read now
Read now
Hui Zhao, Zhi-Jie Lin, Shou-Jie Huang, Juan Li, Xiao-Hui Liu, Meng Guo, Jun Zhang, Ning-Shao Xia, Hui-Rong Pan, Ting Wu & Chang-Gui Li. (2014) Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Human Vaccines & Immunotherapeutics 10:3, pages 740-746.
Read now
Read now
Mahboobeh Safaeian, Troy J. Kemp, David Yuanji Pan, Carolina Porras, Ana Cecilia Rodriguez, Mark Schiffman, Bernal Cortes, Hormuzd Katki, Sholom Wacholder, John T. Schiller, Paula Gonzalez, Kerri Penrose, Douglas R. Lowy, Wim Quint, Leen-Jan van Doorn, Rolando Herrero, Allan Hildesheim & Ligia A. Pinto. (2013) Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses. Human Vaccines & Immunotherapeutics 9:7, pages 1399-1406.
Read now
Read now
Christine Roberts, Ryan Swoyer & Janine Bryan. (2012) Evaluation of the HPV 18 antibody response in Gardasil® vaccinees after 48 mo using a pseudovirion neutralization assay. Human Vaccines & Immunotherapeutics 8:4, pages 431-434.
Read now
Read now
Cecilia M. Roteli-Martins, Paulo Naud, Paola De Borba, Julio C. Teixeira, Newton S. De Carvalho, Toufik Zahaf, Nervo Sanchez, Brecht Geeraerts & Dominique Descamps. (2012) Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine. Human Vaccines & Immunotherapeutics 8:3, pages 390-397.
Read now
Read now
Barbara Romanowski, Tino F. Schwarz, Linda M. Ferguson, Klaus Peters, Marc Dionne, Karin Schulze, Brian Ramjattan, Peter Hillemanns, Grégory Catteau, Kurt Dobbelaere, Anne Schuind & Dominique Descamps. (2011) Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule. Human Vaccines 7:12, pages 1374-1386.
Read now
Read now
Mark H. Einstein, Mira Baron, Myron J. Levin, Archana Chatterjee, Bradley Fox, Sofia Scholar, Jeffrey Rosen, Nahida Chakhtoura, Dorothée Meric, Francis J. Dessy, Sanjoy Kumar Datta, Dominique Descamps & Gary Dubin. (2011) Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine. Human Vaccines 7:12, pages 1343-1358.
Read now
Read now
Tino F. Schwarz, Marek Spaczynski, Achim Schneider, Jacek Wysocki, Andrzej Galaj, Karin Schulze, Sylviane M. Poncelet, Gregory Catteau, Florence Thomas & Dominique Descamps. (2011) Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Human Vaccines 7:9, pages 958-965.
Read now
Read now
Articles from other publishers (121)
Xiao Zhang, Dan Meng, Hong Li, Xuefeng Li, Jing Li, Ping Hu, Lu Zhao, Rui Wang, Chaonan Zhao, Chunxia Luo, Weihua Gu, Wenlin Gai, Yang Wang & Liangzhi Xie. (2023) Validation of Luminex immunological and competitive Luminex immunological assays for clinical immunogenicity assessment of a 14‐valent recombinant human papillomavirus vaccine. Journal of Medical Virology 95:8.
Crossref
Crossref
Yi Zeng, Anna-Barbara Moscicki, Heide Woo, Chiu-Hsieh Hsu, Troy J. Kemp, Ligia A. Pinto, Eva Szabo, Eileen Dimond, Julie Bauman, Vikrant V. Sahasrabuddhe & H-H Sherry Chow. (2023) HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine. Pediatrics 152:1.
Crossref
Crossref
Troy J. Kemp, Heidi A. Hempel, Yuanji Pan, Daisy Roy, James Cherry, Douglas R. Lowy & Ligia A. Pinto. (2023) Assay Harmonization Study To Measure Immune Response to SARS-CoV-2 Infection and Vaccines: a Serology Methods Study. Microbiology Spectrum 11:3.
Crossref
Crossref
Dekui Qiu, Yue Liu, Zhiping Wang, Zhigang Zhang, Meifeng Nie, Ningshao Xia, Shaowei Li & Qinjian Zhao. (2023) Precision and correlation of ED50 and endpoint titer method in measuring HPV vaccine immunogenicity. Journal of Virological Methods 316, pages 114716.
Crossref
Crossref
Katrina M. Nolan, Brent Seaton, Joseph Antonello, Yuhua Zhang, Lauren Cook, Krystyn Delfino, Leonard J. Rubinstein, Kyeongmi Cheon, Thomas Group, Alain Luxembourg & Sheri Dubey. (2023) Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types. mSphere 8:2.
Crossref
Crossref
Ayushi Singhal, Amrita Singh, Apoorva Shrivastava & Raju Khan. (2023) Epitope imprinted polymeric materials: application in electrochemical detection of disease biomarkers. Journal of Materials Chemistry B 11:5, pages 936-954.
Crossref
Crossref
John T. Schiller, Lauri E. Markowitz, Aimée R. Kreimer & Douglas R. Lowy. 2023. Plotkin's Vaccines. Plotkin's Vaccines
484
513.e11
.
Lei Bei, Xiao Zhang, Dan Meng, Shuman Gao, Jilei Jia, Dandan Zhao, Chunxia Luo, Xuefeng Li, Hongbin Qiu & Liangzhi Xie. (2022) Immunogenicity correlation in cynomolgus monkeys between Luminex‐based total IgG immunoassay and pseudovirion‐based neutralization assay for a 14‐valent recombinant human papillomavirus vaccine. Journal of Medical Virology 94:8, pages 3946-3955.
Crossref
Crossref
Priya R. Prabhu, Joseph J. Carter & Denise A. Galloway. (2022) B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination. Vaccines 10:6, pages 837.
Crossref
Crossref
Sabrina H. Tsang, John T. Schiller, Carolina Porras, Troy J. Kemp, Rolando Herrero, John Schussler, Monica S. Sierra, Bernal Cortes, Allan Hildesheim, Douglas R. Lowy, Ana Cecilia Rodríguez, Byron Romero, Nicolas Çuburu, Jaimie Z. Shing, Ligia A. Pinto, Joshua N. Sampson, Aimée R. Kreimer, Bernal Cortés, Paula González, Rolando Herrero, Silvia E. Jiménez, Carolina Porras, Ana Cecilia Rodríguez, Allan Hildesheim, Aimée R. Kreimer, Douglas R. Lowy, Mark Schiffman, John T. Schiller, Mark Sherman, Sholom Wacholder, Ligia A. Pinto, Troy J. Kemp, Mary K. Sidawy, Wim Quint, Leen-Jan van Doorn, Linda Struijk, Joel M. Palefsky, Teresa M. Darragh & Mark H. Stoler. (2022) HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. npj Vaccines 7:1.
Crossref
Crossref
Andrea Trevisan, Michel D. Wissing, Carole Dagenais, Pierre Forest, Agnihotram V. Ramanakumar, Ann N. Burchell, Eduardo L. Franco, François Coutlée & Michel Couillard. (2021) Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18. Journal of General Virology 102:5.
Crossref
Crossref
Joseph E Tota, Frank Struyf, Allan Hildesheim, Paula Gonzalez, Martin Ryser, Rolando Herrero, John Schussler, Naveen Karkada, Ana Cecilia Rodriguez, Nicolas Folschweiller, Carolina Porras, Mark Schiffman, John T Schiller, Wim Quint, Aimée R Kreimer, Matti Lehtinen, Cosette M Wheeler & Joshua N Sampson. (2021) Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. The Journal of Infectious Diseases 223:9, pages 1576-1581.
Crossref
Crossref
Adolfo Pedroza-Saavedra, Angelica Nallelhy Rodriguez-Ocampo, Azucena Salazar-Piña, Aislinn Citlali Perez-Morales, Lilia Chihu-Amparan, Minerva Maldonado-Gama, Aurelio Cruz-Valdez, Fernando Esquivel-Guadarrama & Lourdes Gutierrez-Xicotencatl. (2021) Differential Antibody Response against Conformational and Linear Epitopes of the L1 Proteins from Human Papillomavirus Types 16/18 Is Observed in Vaccinated Women or with Uterine Cervical Lesions. Vaccines 9:5, pages 442.
Crossref
Crossref
Livia Mazzini, Donata Martinuzzi, Inesa Hyseni, Linda Benincasa, Eleonora Molesti, Elisa Casa, Giulia Lapini, Pietro Piu, Claudia Maria Trombetta, Serena Marchi, Ilaria Razzano, Alessandro Manenti & Emanuele Montomoli. (2021) Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. Journal of Immunological Methods 489, pages 112937.
Crossref
Crossref
Ting Zhang, Xue Chen, Guoyang Liao, Meili Hu, Jianqing Xu & Xuemei Xu. (2020) Induction of cross‐neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines. Journal of Medical Virology 92:12, pages 3750-3758.
Crossref
Crossref
Inge Pietersen, Albertha van Zyl, Edward Rybicki & Inga Hitzeroth. (2020) Novel Production of Bovine Papillomavirus Pseudovirions in Tobacco Plants. Pathogens 9:12, pages 996.
Crossref
Crossref
Amin Azimi, Sheida Heidarian, Homa Zamani, Nastaran Taleghani, Mohsen Dehghani & Ehsan Seyedjafari. (2020) Optimized dose of synthetic analogues of Monophosphoryl lipid A as an effective alternative for formulating recombinant human papillomavirus vaccine. Biologicals 68, pages 60-64.
Crossref
Crossref
Zheng Quan Toh, Laura He, Catherine Chen, Angela Huang, Fiona M. Russell, Suzanne M. Garland, Rita Reyburn, Tupou Ratu, Evelyn Tuivaga, Ian H. Frazer, E. Kim Mulholland & Paul V. Licciardi. (2020) Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method. Frontiers in Immunology 11.
Crossref
Crossref
Aimée R Kreimer, Joshua N Sampson, Carolina Porras, John T Schiller, Troy Kemp, Rolando Herrero, Sarah Wagner, Joseph Boland, John Schussler, Douglas R Lowy, Stephen Chanock, David Roberson, Mónica S Sierra, Sabrina H Tsang, Mark Schiffman, Ana Cecilia Rodriguez, Bernal Cortes, Mitchell H Gail, Allan Hildesheim, Paula Gonzalez & Ligia A Pinto. (2020) Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. JNCI: Journal of the National Cancer Institute 112:10, pages 1038-1046.
Crossref
Crossref
Qi Chen, Hui Zhao, Xingmei Yao, Zhijie Lin, Juan Li, Bizhen Lin, Rui Wang, Yue Huang, Yingying Su, Ting Wu, Changgui Li, Huirong Pan, Shoujie Huang, Jun Zhang & Ningshao Xia. (2020) Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages. Vaccine 38:39, pages 6096-6102.
Crossref
Crossref
Joseph E Tota, Frank Struyf, Joshua N Sampson, Paula Gonzalez, Martin Ryser, Rolando Herrero, John Schussler, Naveen Karkada, Ana Cecilia Rodriguez, Nicolas Folschweiller, Carolina Porras, Mark Schiffman, John T Schiller, Wim Quint, Aimée R Kreimer, Cosette M Wheeler & Allan Hildesheim. (2020) Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. JNCI: Journal of the National Cancer Institute 112:8, pages 818-828.
Crossref
Crossref
Reinaldo F Cooke, Rafael Paiva & K G Pohler. (2020) Technical Note: Using enzyme-linked immunosorbent assays to evaluate humoral responses to vaccination against respiratory viruses in beef cattle. Journal of Animal Science 98:8.
Crossref
Crossref
Yi Zeng, Anna-Barbara Moscicki, Vikrant V. Sahasrabuddhe, Francisco Garcia, Heide Woo, Chiu-Hsieh Hsu, Eva Szabo, Eileen Dimond, Susan Vanzzini, Angelica Mondragon, Valerie Butler, Hillary DeRose & H.-H. Sherry Chow. (2019) A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9–11 year-old girls and boys – clinical protocol. BMC Cancer 19:1.
Crossref
Crossref
Feng‐Cai Zhu, Shang‐Ying Hu, Ying Hong, Yue‐Mei Hu, Xun Zhang, Yi‐Ju Zhang, Qin‐Jing Pan, Wen‐Hua Zhang, Fang‐Hui Zhao, Cheng‐Fu Zhang, Xiaoping Yang, Jia‐Xi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Qian Zhang, Hong Wang, Changrong Wang, Jun Bi, Shiyin Xue, Lingling Shen, Yan‐Shu Zhang, Yunkun He, Haiwen Tang, Naveen Karkada, Pemmaraju Suryakiran, Dan Bi & Frank Struyf. (2019) Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial. Cancer Medicine 8:14, pages 6195-6211.
Crossref
Crossref
Dominique Rosillon, Laurence Baril, Maria Rowena Del Rosario‐Raymundo, Cosette Marie Wheeler, Susan Rachel Skinner, Suzanne Marie Garland, Jorge Salmeron, Eduardo Lazcano‐Ponce, Carlos Santiago Vallejos, Tanya Stoney, Bram ter Harmsel, Timothy Yong Kuei Lim, Swee Chong Quek, Galina Minkina, Shelly Ann McNeil, Celine Bouchard, Kah Leng Fong, Deborah Money, Arunachalam Ilancheran, Alevtina Savicheva, Margaret Cruickshank, Archana Chatterjee, Alison Fiander, Mark Martens, Marie Cecile Bozonnat, Frank Struyf, Gary Dubin & Xavier Castellsagué. (2019) Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies. Cancer Medicine 8:10, pages 4938-4953.
Crossref
Crossref
Katherine H. Parker, Troy J. Kemp, Kimberly Isaacs-Soriano, Martha Abrahamsen, Yuanji Pan, Eduardo Lazcano-Ponce, Jorge Salmeron, Ligia A. Pinto & Anna R. Giuliano. (2019) HPV-specific antibodies at the oral cavity up to 30 months after the start of vaccination with the quadrivalent HPV vaccine among mid-adult aged men. Vaccine 37:21, pages 2864-2869.
Crossref
Crossref
Eduardo Lazcano-Ponce, Leticia Torres-Ibarra, Aurelio Cruz-Valdez, Jorge Salmerón, Tonatiuh Barrientos-Gutiérrez, Javier Prado-Galbarro, Margaret Stanley, Nubia Muñoz, Rolando Herrero & Mauricio Hernández-Ávila. (2019) Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination. The Journal of Infectious Diseases 219:1, pages 41-49.
Crossref
Crossref
Herney Andrés García-Perdomo, Julio Cesar Osorio, Adrian Fernandez, James Alejandro Zapata-Copete & Andrés Castillo. (2019) The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis. Epidemiology and Infection 147.
Crossref
Crossref
Chuanlai Xu, Hua Kuang & Liguang XuChuanlai Xu, Hua Kuang & Liguang Xu. 2019. Food Immunoassay. Food Immunoassay
155
176
.
Cai Zhang, Xiaofen Huang, Siyi Chen, Yike Li, Yufang Li, Xin Wang, Jixian Tang, Lin Xia, Zhijie Lin, Wenxin Luo, Tingdong Li, Shaowei Li, Jun Zhang, Ningshao Xia & Qinjian Zhao. (2018) Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid. Vaccine 36:45, pages 6761-6771.
Crossref
Crossref
Ligia A. Pinto, Joakim Dillner, Simon Beddows & Elizabeth R. Unger. (2018) Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine 36:32, pages 4792-4799.
Crossref
Crossref
Mahboobeh Safaeian, Xavier Castellsagué, Allan Hildesheim, Sholom Wacholder, Mark H Schiffman, Marie-Cécile Bozonnat, Laurence Baril, Dominique Rosillon, A Chatterjee, S-N Chow, N De Carvalho, Del Rosario Raymundo, F Diaz Mitoma, G Dubin, S Garland, M J Germar, P Gonzalez, D M Harper, U Jaisamrarn, A R Kreimer, M Lehtinen, P Naud, J Paavonen, K Peters, W Poppe, C Porras, J Salmeròn, M Sherman, S R Skinner, F Struyf, J Teixeira, W Tjalma & C M Wheeler. (2018) Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials. The Journal of Infectious Diseases 218:1, pages 84-94.
Crossref
Crossref
Katherine H. Parker, Troy J. Kemp, Yuanji Pan, Zhen Yang, Anna R. Giuliano & Ligia A. Pinto. (2018) Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges. Vaccine 36:19, pages 2705-2711.
Crossref
Crossref
Mahboobeh Safaeian, Joshua N. Sampson, Yuanji Pan, Carolina Porras, Troy J. Kemp, Rolando Herrero, Wim Quint, Leen Jan van Doorn, John Schussler, Douglas R. Lowy, John Schiller, Mark T. Schiffman, Ana Cecilia Rodriguez, Mitchell H. Gail, Allan Hildesheim, Paula Gonzalez, Ligia A. Pinto, Aimée R. Kreimer, González Paula, Rolando Herrero, Silvia E. Jiménez, Carolina Porras, Ana Cecilia Rodríguez, Allan Hildesheim, Aimée R. Kreimer, Douglas R. Lowy, Mark Schiffman, John T. Schiller, Mark Sherman, Sholom Wacholder, Ligia A. Pinto, Troy J. Kemp, Mary K. Sidawy, Wim Quint, Leen-Jan van Doorn, Linda Struijk, Joel M. Palefsky, Teresa M. Darragh & Mark H. Stoler. (2018) Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. JNCI: Journal of the National Cancer Institute 110:2, pages 205-212.
Crossref
Crossref
Begum AkuzumSinae KimTam Thanh NguyenJeawoo HongSiyoung LeeEunhye KimJoohee KimYeook ChoiHyunjhung JhunYoungmin LeeHyunwoo KimDong Hyun SohnSoohyun Kim. (2018) L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine. Immune Network 18:3.
Crossref
Crossref
Ting Fan Leung, Anthony Pak-Yin Liu, Fong Seng Lim, Franck Thollot, Helen May Lin Oh, Bee Wah Lee, Lars Rombo, Ngiap Chuan Tan, Roman Rouzier, Stéphanie De Simoni, Pemmaraju Suryakiran, Marjan Hezareh, Florence Thomas, Nicolas Folschweiller & Frank Struyf. (2018) Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9–14 years: Results to month 36 from a randomized trial. Vaccine 36:1, pages 98-106.
Crossref
Crossref
John T. Schiller, Lauri E. Markowitz, Allan Hildesheim & Douglas R. Lowy. 2018. Plotkin's Vaccines. Plotkin's Vaccines
430
455.e10
.
Parinda A. Mehta, Sharon Sauter, Xue Zhang, Stella M. Davies, Suzanne I. Wells, Kasiani C. Myers, Gitika Panicker, Elizabeth R. Unger & Melinda Butsch Kovacic. (2017) Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia. Vaccine 35:48, pages 6712-6719.
Crossref
Crossref
Eva Hamsikova, Jana Smahelova, Viera Ludvikova, Martina Salakova, Jana Rychla, Jana Skrenkova, Lukas Rob & Ruth Tachezy. (2017) The prevalence of HPV infections in HPV-vaccinated women from the general population. APMIS 125:6, pages 585-595.
Crossref
Crossref
Fei Yin, Yajun Wang, Na Chen, Dunquan Jiang, Yefeng Qiu, Yan Wang, Mei Yan, Jianping Chen, Haijiang Zhang & Yongjiang Liu. (2017) A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model. Papillomavirus Research 3, pages 85-90.
Crossref
Crossref
Fumiko Endo, Tsutomu Tabata, Daichi Sadato, Machiko Kawamura, Noriyuki Ando, Keisuke Oboki, Masako Ukaji, Kaoru Kobayashi, Yukuharu Kobayashi, Tomoaki Ikeda & Futoshi Shibasaki. (2017) Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies. PLOS ONE 12:2, pages e0171314.
Crossref
Crossref
Joseph E. Tota, Frank Struyf, Marko Merikukka, Paula Gonzalez, Aimée R. Kreimer, Dan Bi, Xavier Castellsagué, Newton S. de Carvalho, Suzanne M. Garland, Diane M. Harper, Naveen Karkada, Klaus Peters, Willy A. J. Pope, Carolina Porras, Wim Quint, Ana Cecilia Rodriguez, Mark Schiffman, John Schussler, S. Rachel Skinner, Júlio Cesar Teixeira, Allan Hildesheim & Matti Lehtinen. (2017) Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. Journal of the National Cancer Institute 109:7, pages djw300.
Crossref
Crossref
Shitaldas J. Pamnani, Staci L. Sudenga, Raphael Viscidi, Dana E. Rollison, B. Nelson Torres, Donna J. Ingles, Martha Abrahamsen, Luisa L. Villa, Eduardo Lazcano-Ponce, Jorge Salmeron, Manuel Quiterio, Yangxin Huang, Amy Borenstein & Anna R. Giuliano. (2016) Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study. Cancer Research 76:20, pages 6066-6075.
Crossref
Crossref
Ligia A. Pinto, Troy J. Kemp, B. Nelson Torres, Kimberly Isaacs-Soriano, Donna Ingles, Martha Abrahamsen, Yuanji Pan, Eduardo Lazcano-Ponce, Jorge Salmeron & Anna R. Giuliano. (2016) Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. Journal of Infectious Diseases 214:8, pages 1276-1283.
Crossref
Crossref
Cosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, Suzanne M Garland, Archana Chatterjee, Eduardo Lazcano-Ponce, Jorge Salmerón, Shelly McNeil, Jack T Stapleton, Céline Bouchard, Mark G Martens, Deborah M Money, Swee Chong Quek, Barbara Romanowski, Carlos S Vallejos, Bram ter Harmsel, Vera Prilepskaya, Kah Leng Fong, Henry Kitchener, Galina Minkina, Yong Kuei Timothy Lim, Tanya Stoney, Nahida Chakhtoura, Margaret E Cruickshank, Alevtina Savicheva, Daniel Pereira da Silva, Murdo Ferguson, Anco C Molijn, Wim G V Quint, Karin Hardt, Dominique Descamps, Pemmaraju V Suryakiran, Naveen Karkada, Brecht Geeraerts, Gary Dubin & Frank Struyf. (2016) Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. The Lancet Infectious Diseases 16:10, pages 1154-1168.
Crossref
Crossref
Thanyawee Puthanakit, Li-Min Huang, Cheng-Hsun Chiu, Ren-Bin Tang, Tino F. Schwarz, Susanna Esposito, Louise Frenette, Carlo Giaquinto, Shelly McNeil, Paul Rheault, Paolo Durando, Michael Horn, Maximilian Klar, Sylviane Poncelet, Stéphanie De Simoni, Damien Friel, Benoit De Muynck, Pemmaraju V. Suryakiran, Marjan Hezareh, Dominique Descamps, Florence Thomas & Frank Struyf. (2016) Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years. Journal of Infectious Diseases 214:4, pages 525-536.
Crossref
Crossref
David Mesher, Elaine Stanford, Joanne White, Jamie Findlow, Rosalind Warrington, Sukamal Das, Richard Pebody, Ray Borrow & Kate Soldan. (2016) HPV Serology Testing Confirms High HPV Immunisation Coverage in England. PLOS ONE 11:3, pages e0150107.
Crossref
Crossref
Daniel C. Beachler, Aimée R. Kreimer, Mark Schiffman, Rolando Herrero, Sholom Wacholder, Ana Cecilia Rodriguez, Douglas R. Lowy, Carolina Porras, John T. Schiller, Wim Quint, Silvia Jimenez, Mahboobeh Safaeian, Linda Struijk, John Schussler, Allan Hildesheim & Paula Gonzalez. (2015) Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. Journal of the National Cancer Institute 108:1, pages djv302.
Crossref
Crossref
Anna Godi, Sara L. Bissett, Elizabeth Miller & Simon Beddows. (2015) Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine. PLOS ONE 10:10, pages e0140926.
Crossref
Crossref
Andrea Piana, Ilaria Epifano, Sara L. Bissett, Clementina Cocuzza, Simon Beddows, Tiziana Dell'Anna & Anna Godi. (2015) Amino acid motifs in both the major and minor capsid proteins of HPV51 impact antigenicity and infectivity. Journal of General Virology 96:7, pages 1842-1849.
Crossref
Crossref
Dan Apter, Cosette M. Wheeler, Jorma Paavonen, Xavier Castellsagué, Suzanne M. Garland, S. Rachel Skinner, Paulo Naud, Jorge Salmerón, Song-Nan Chow, Henry C. Kitchener, Julio C. Teixeira, Unnop Jaisamrarn, Genara Limson, Anne Szarewski, Barbara Romanowski, Fred Y. Aoki, Tino F. Schwarz, Willy A. J. Poppe, F. Xavier Bosch, Adrian Mindel, Philippe de Sutter, Karin Hardt, Toufik Zahaf, Dominique Descamps, Frank Struyf, Matti Lehtinen & Gary Dubin. (2015) Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial. Clinical and Vaccine Immunology 22:4, pages 361-373.
Crossref
Crossref
T Schwarz, M Spaczynski, A Kaufmann, J Wysocki, A Gałaj, K Schulze, P Suryakiran, F Thomas & D Descamps. (2014)
Persistence of immune responses to the
HPV
‐16/18
AS
04‐adjuvanted vaccine in women aged 15–55 years and first‐time modelling of antibody responses in mature women: results from an open‐label 6–year follow‐up study
. BJOG: An International Journal of Obstetrics & Gynaecology 122:1, pages 107-118.
Crossref
Crossref
Zusen Weng & Qinjian Zhao. 2015. Protein-Protein Interactions. Protein-Protein Interactions
341
352
.
Proscovia B Namujju, Emma Pajunen, Aline Simen-Kapeu, Lea Hedman, Marko Merikukka, Helja-Marja Surcel, Reinhard Kirnbauer, Dan Apter, Jorma Paavonen, Klaus Hedman & Matti Lehtinen. (2014) Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study. BMC Research Notes 7:1.
Crossref
Crossref
Hilary A Robbins, Yan Li, Carolina Porras, Michael Pawlita, Arpita Ghosh, Ana Cecilia Rodriguez, Mark Schiffman, Sholom Wacholder, Troy J Kemp, Paula Gonzalez, John Schiller, Douglas Lowy, Mark Esser, Katie Matys, Wim Quint, Leen-Jan van Doorn, Rolando Herrero, Ligia A Pinto, Allan Hildesheim, Tim Waterboer & Mahboobeh Safaeian. (2014) Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infectious Diseases 14:1.
Crossref
Crossref
S Rachel Skinner, Anne Szarewski, Barbara Romanowski, Suzanne M Garland, Eduardo Lazcano-Ponce, Jorge Salmerón, M Rowena Del Rosario-Raymundo, René H M Verheijen, Swee Chong Quek, Daniel P da Silva, Henry Kitchener, Kah Leng Fong, Céline Bouchard, Deborah M Money, Arunachalam Ilancheran, Margaret E Cruickshank, Myron J Levin, Archana Chatterjee, Jack T Stapleton, Mark Martens, Wim Quint, Marie-Pierre David, Dorothée Meric, Karin Hardt, Dominique Descamps, Brecht Geeraerts, Frank Struyf & Gary Dubin. (2014) Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. The Lancet 384:9961, pages 2213-2227.
Crossref
Crossref
Feng‐Cai Zhu, Wen Chen, Yue‐Mei Hu, Ying Hong, Juan Li, Xun Zhang, Yi‐Ju Zhang, Qin‐Jing Pan, Fang‐Hui Zhao, Jia‐Xi Yu, Yan‐Shu Zhang, Xiaoping Yang, Cheng‐Fu Zhang, Haiwen Tang, Helen Zhang, Marie Lebacq, Marie‐Pierre David, Sanjoy K Datta, Frank Struyf, Dan Bi & Dominique Descamps. (2014) Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial. International Journal of Cancer 135:11, pages 2612-2622.
Crossref
Crossref
Fang‐Hui Zhao, Feng‐Cai Zhu, Wen Chen, Juan Li, Yue‐Mei Hu, Ying Hong, Yi‐Ju Zhang, Qin‐Jing Pan, Jia‐Hong Zhu, Xun Zhang, Yong Chen, Haiwen Tang, Helen Zhang, Christelle Durand, Sanjoy K. Datta, Frank Struyf & Dan Bi. (2014) Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18–25 years enrolled in a clinical trial. International Journal of Cancer 135:11, pages 2604-2611.
Crossref
Crossref
Krystle A. Lang Kuhs, Carolina Porras, John T. Schiller, Ana Cecilia Rodriguez, Mark Schiffman, Paula Gonzalez, Sholom Wacholder, Arpita Ghosh, Yan Li, Douglas R. Lowy, Aimée R. Kreimer, Sylviane Poncelet, John Schussler, Wim Quint, Leen-Jan van Doorn, Mark E. Sherman, Mary Sidawy, Rolando Herrero, Allan Hildesheim, Mahboobeh Safaeian, Krystle A. Lang Kuhs, John T. Schiller, Mark Schiffman, Sholom Wacholder, Douglas R. Lowy, Aimée R. Kreimer, Mark E. Sherman, Allan Hildesheim, Mahboobeh Safaeian, Carolina Porras, Ana Cecilia Rodriguez, Paula Gonzalez, Rolando Herrero, Paula Gonzalez, Rolando Herrero, Arpita Ghosh, Yan Li, Sylviane Poncelet, John Schussler, Wim Quint, Leen-Jan van Doorn, Mary Sidawy, Steve Self, Adriana Benavides, Luis Diego Calzada, Ruth Karron, Ritu Nayar, Nancy Roach, Joanna Cain, Diane Davey, David DeMets, Francisco Fuster, Ann Gershon, Elizabeth Holly, Henriette Raventós, Wasima Rida, Luis Rosero-Bixby, Kristen Suthers, Silvia Lara, Sarah Thomas, Mario Alfaro, Manuel Barrantes, M. Concepción Bratti, Fernando Cárdenas, Bernal Cortés, Albert Espinoza, Yenory Estrada, Paula González, Diego Guillén, Roland Herrero, Silvia E. Jiménez, Jorge Morales, Luis Villegas, Lidia Ana Morera, Elmer Pérez, Carolina Porras, Ana Cecilia Rodríguez, Libia Rivas, Enrique Freer, José Bonilla, Alfanso García-Piñeres, Sandra Silva, Ivannia Atmella, Margarita Ramírez, Allan Hildesheim, Aimée R. Kreimer, Douglas R. Lowy, Nora Macklin, Mark Schiffman, John T. Schiller, Mark Sherman, Diane Solomon, Sholom Wacholder, Ligia Pinto, Troy Kemp, Claire Eklund, Martha Hutchinson, Mary Sidawy, Wim Quint & Leen-Jan van Doorn. (2014) Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates. American Journal of Epidemiology 180:6, pages 599-607.
Crossref
Crossref
Allan Hildesheim, Sholom Wacholder, Gregory Catteau, Frank Struyf, Gary Dubin & Rolando Herrero. (2014) Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32:39, pages 5087-5097.
Crossref
Crossref
Xavier Castellsagué, Paulo Naud, Song-Nan Chow, Cosette M. Wheeler, Maria Julieta V. Germar, Matti Lehtinen, Jorma Paavonen, Unnop Jaisamrarn, Suzanne M. Garland, Jorge Salmerón, Dan Apter, Henry Kitchener, Julio C. Teixeira, S. Rachel Skinner, Genara Limson, Anne Szarewski, Barbara Romanowski, Fred Y. Aoki, Tino F. Schwarz, Willy A. J. Poppe, F. Xavier Bosch, Newton S. de Carvalho, Klaus Peters, Wiebren A. A. Tjalma, Mahboobeh Safaeian, Alice Raillard, Dominique Descamps, Frank Struyf, Gary Dubin, Dominique Rosillon & Laurence Baril. (2014) Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA. The Journal of Infectious Diseases 210:4, pages 517-534.
Crossref
Crossref
Pierre Van Damme, Geert Leroux-Roels, Philippe Simon, Jean-Michel Foidart, Gilbert Donders, Karel Hoppenbrouwers, Myron Levin, Fabian Tibaldi, Sylviane Poncelet, Philippe Moris, Francis Dessy, Sandra L. Giannini, Dominique Descamps & Gary Dubin. (2014) Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials. Vaccine 32:29, pages 3694-3705.
Crossref
Crossref
Alinea S. Noronha, Lauri E. Markowitz & Eileen F. Dunne. (2014) Systematic review of human papillomavirus vaccine coadministration. Vaccine 32:23, pages 2670-2674.
Crossref
Crossref
L. Toft, M. Storgaard, M. Muller, P. Sehr, J. Bonde, M. Tolstrup, L. Ostergaard & O. S. Sogaard. (2013) Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults: A Randomized, Double-Blind Clinical Trial. Journal of Infectious Diseases 209:8, pages 1165-1173.
Crossref
Crossref
Sara L. Bissett, Eve Draper, Richard E. Myers, Anna Godi & Simon Beddows. (2014) Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Vaccine 32:10, pages 1139-1146.
Crossref
Crossref
Eduardo Lazcano-Ponce, Margaret Stanley, Nubia Muñoz, Leticia Torres, Aurelio Cruz-Valdez, Jorge Salmerón, Rosalba Rojas, Rolando Herrero & Mauricio Hernández-Ávila. (2014) Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 32:6, pages 725-732.
Crossref
Crossref
Blanche P. Alter, Neelam Giri, Yuanji Pan, Sharon A. Savage & Ligia A. Pinto. (2014) Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes. Vaccine 32:10, pages 1169-1173.
Crossref
Crossref
Joelle Brown, Kathy Baisley, Bazil Kavishe, John Changalucha, Aura Andreasen, Philippe Mayaud, Balthazar Gumodoka, Saidi Kapiga, Richard Hayes & Deborah Watson-Jones. (2014) Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania. Vaccine 32:5, pages 611-617.
Crossref
Crossref
Rachna Sharma, Jimmy T. Efird, Aung Chein, Elizabeth A. Holly, Mel Krajden, J. Michael Berry, Teresa M. Darragh, Naomi Jay & Joel M. Palefsky. (2013) Prevalence and Risk Factors for Neutralizing Antibodies to Human Papillomavirus Types 16 and 18 in HIV-Positive Men Who Have Sex With Men. JAIDS Journal of Acquired Immune Deficiency Syndromes 64:5, pages 479-487.
Crossref
Crossref
Mahboobeh Safaeian, Carolina Porras, Yuanji Pan, Aimee Kreimer, John T. Schiller, Paula Gonzalez, Douglas R. Lowy, Sholom Wacholder, Mark Schiffman, Ana C. Rodriguez, Rolando Herrero, Troy Kemp, Gloriana Shelton, Wim Quint, Leen-Jan van Doorn, Allan Hildesheim & Ligia A. Pinto. (2013) Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. Cancer Prevention Research 6:11, pages 1242-1250.
Crossref
Crossref
Y Fang, T Zhang, L Lidell, X Xu, N Lycke & Z Xiang. (2013) The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization. Mucosal Immunology 6:6, pages 1168-1178.
Crossref
Crossref
Lynette Denny, Bronwyn Hendricks, Chivaugn Gordon, Florence Thomas, Marjan Hezareh, Kurt Dobbelaere, Christelle Durand, Caroline Hervé & Dominique Descamps. (2013) Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study. Vaccine 31:48, pages 5745-5753.
Crossref
Crossref
Peter Sehr, Ivonne Rubio, Hanna Seitz, Kerstin Putzker, Lis Ribeiro-M?ller, Michael Pawlita & Martin M?ller. (2013) High-Throughput Pseudovirion-Based Neutralization Assay for Analysis of Natural and Vaccine-Induced Antibodies against Human Papillomaviruses. PLoS ONE 8:10, pages e75677.
Crossref
Crossref
Mirte Scherpenisse, Rutger M. Schepp, Madelief Mollers, Chris J. L. M. Meijer, Guy A. M. Berbers & Fiona R. M. van der Klis. (2013) Characteristics of HPV-Specific Antibody Responses Induced by Infection and Vaccination: Cross-Reactivity, Neutralizing Activity, Avidity and IgG Subclasses. PLoS ONE 8:9, pages e74797.
Crossref
Crossref
Rolando Herrero, Wim Quint, Allan Hildesheim, Paula Gonzalez, Linda Struijk, Hormuzd A. Katki, Carolina Porras, Mark Schiffman, Ana Cecilia Rodriguez, Diane Solomon, Silvia Jimenez, John T. Schiller, Douglas R. Lowy, Leen-Jan van Doorn, Sholom Wacholder & Aimée R. Kreimer. (2013) Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. PLoS ONE 8:7, pages e68329.
Crossref
Crossref
Frank Tanser, Kyle G. Jones, Johannes Viljoen, John Imrie, Erofili Grapsa & Marie-Louise Newell. (2013) Human Papillomavirus Seropositivity and Subsequent Risk of HIV Acquisition in Rural South African Women. Sexually Transmitted Diseases 40:7, pages 601-606.
Crossref
Crossref
Papa Salif Sow, Deborah Watson-Jones, Nancy Kiviat, John Changalucha, Khardiata Diallo Mbaye, Joelle Brown, Kouro Bousso, Bazil Kavishe, Aura Andreasen, Macoumba Toure, Saidi Kapiga, Philippe Mayaud, Richard Hayes, Marie Lebacq, Marjan Herazeh, Florence Thomas & Dominique Descamps. (2013) Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women. The Journal of Infectious Diseases 207:11, pages 1753-1763.
Crossref
Crossref
Helena Faust, Kristin Andersson, Ola Forslund & Joakim Dillner. (2013) Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin. Journal of General Virology 94:5, pages 1096-1103.
Crossref
Crossref
Péter Bősze. (2013) The first vaccine against cancer: the human papillomavirus vaccine. Orvosi Hetilap 154:16, pages 603-618.
Crossref
Crossref
Shih-Wen Lin, Arpita Ghosh, Carolina Porras, Sarah C. Markt, Ana Cecilia Rodriguez, Mark Schiffman, Sholom Wacholder, Troy J. Kemp, Ligia A. Pinto, Paula Gonzalez, Nicolas Wentzensen, Mark T. Esser, Katie Matys, Ariane Meuree, Wim Quint, Leen-Jan van Doorn, Rolando Herrero, Allan Hildesheim & Mahboobeh Safaeian. (2013) HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays. PLoS ONE 8:1, pages e53067.
Crossref
Crossref
John T. Schiller, Douglas R. Lowy & Lauri E. Markowitz. 2013. Vaccines. Vaccines
235
256
.
Xixiu Xie, Yanchun Liu, Ting Zhang, Yanying Xu, Qifeng Bao, Xue Chen, Hongyang Liu & Xuemei Xu. (2012) Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies. Archives of Virology 158:1, pages 193-199.
Crossref
Crossref
A.-B. Moscicki, C.M. Wheeler, B. Romanowski, J. Hedrick, S. Gall, D. Ferris, S. Poncelet, T. Zahaf, P. Moris, B. Geeraerts, D. Descamps & A. Schuind. (2012) Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine 31:1, pages 234-241.
Crossref
Crossref
John T. Schiller, Xavier Castellsagué & Suzanne M. Garland. (2012) A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine 30, pages F123-F138.
Crossref
Crossref
Marek Petráš, Tomáš Sýkora, Ctirad Andrýs & Marcela Drahošová. (2012) Post-vaccination anti-human papillomavirus antibody seroprevalence among Czech teenaged girls and women. International Journal of Gynecology & Obstetrics 119:2, pages 178-181.
Crossref
Crossref
Mirte Scherpenisse, Madelief Mollers, Rutger M. Schepp, Hein J. Boot, Hester E. de Melker, Chris J.L.M. Meijer, Guy A.M. Berbers & Fiona R.M. van der Klis. (2012) Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine 30:47, pages 6686-6693.
Crossref
Crossref
M.G. Gonda, X. Fang, G.A. Perry & C. Maltecca. (2012) Measuring bovine viral diarrhea virus vaccine response: Using a commercially available ELISA as a surrogate for serum neutralization assays. Vaccine 30:46, pages 6559-6563.
Crossref
Crossref
Mahboobeh Safaeian, Arpita Ghosh, Carolina Porras, Shih-Wen Lin, Ana Cecilia Rodriguez, Mark Schiffman, Sholom Wacholder, Troy Kemp, Paula Gonzalez, Nicolas Wentzensen, Mark Esser, Ariane Meuree, Katie Matys, Wim Quint, Leen-Jan van Doorn, Mark E. Sherman, Rolando Herrero, Ligia A. Pinto & Allan Hildesheim. (2012) Direct Comparison of HPV16 Serological Assays Used to Define HPV-Naïve Women in HPV Vaccine Trials. Cancer Epidemiology, Biomarkers & Prevention 21:9, pages 1547-1554.
Crossref
Crossref
A. Szarewski, W.A.J. Poppe, S.R. Skinner, C.M. Wheeler, J. Paavonen, P. Naud, J. Salmeron, S.‐N. Chow, D. Apter, H. Kitchener, X. Castellsagué, J.C. Teixeira, J. Hedrick, U. Jaisamrarn, G. Limson, S. Garland, B. Romanowski, F.Y. Aoki, T.F. Schwarz, F.X. Bosch, D.M. Harper, K. Hardt, T. Zahaf, D. Descamps, F. Struyf, M. Lehtinen & G. Dubin. (2011) Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18. International Journal of Cancer 131:1, pages 106-116.
Crossref
Crossref
Ji Eun Han, Seo Ri Wui, Shin Ae Park, Na Gyong Lee, Kwang Sung Kim, Yang Je Cho, Hyoung Jin Kim & Hong-Jin Kim. (2012) Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice. Vaccine 30:28, pages 4127-4134.
Crossref
Crossref
Joseph G. Dauner, Yuanji Pan, Allan Hildesheim, Troy J. Kemp, Carolina Porras & Ligia A. Pinto. (2012) Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Molecular and Cellular Probes 26:2, pages 73-80.
Crossref
Crossref
Sara L. Bissett, Dianna Wilkinson, Kate I. Tettmar, Nicky Jones, Elaine Stanford, Gitika Panicker, Helena Faust, Ray Borrow, Kate Soldan, Elizabeth R. Unger, Joakim Dillner, Philip Minor & Simon Beddows. (2012) Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology. Clinical and Vaccine Immunology 19:3, pages 449-451.
Crossref
Crossref
H. Peigue-Lafeuille & D. Floret. (2012) Mise au point sur les recommandations fran?aises de la vaccination contre les infections ? papillomavirus. Journal des Anti-infectieux 14:1, pages 42-49.
Crossref
Crossref
Beibei Lu, Raphael P. Viscidi, Yougui Wu, Ji-Hyun Lee, Alan G. Nyitray, Luisa L. Villa, Eduardo Lazcano-Ponce, Roberto J. Carvalho da Silva, Maria Luiza Baggio, Manuel Quiterio, Jorge Salmeron, Danelle C. Smith, Martha E. Abrahamsen, Mary R. Papenfuss, Heather G. Stockwell & Anna R. Giuliano. (2012) Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men. Cancer Research 72:3, pages 676-685.
Crossref
Crossref
Dr. M. Dawar, Ms. T. Harris & Dr. S. McNeil. (2012) Update on Human Papillomavirus (HPV) Vaccines. Canada Communicable Disease Report 38:ACS-1, pages 1-62.
Crossref
Crossref
Carina Eklund, Elizabeth R. Unger, Denise Nardelli-Haefliger, Tiequn Zhou & Joakim Dillner. (2012) International collaborative proficiency study of Human Papillomavirus type 16 serology. Vaccine 30:2, pages 294-299.
Crossref
Crossref
Court Pedersen, Morten Breindahl, Naresh Aggarwal, Johan Berglund, György Oroszlán, Sven Arne Silfverdal, Péter Szüts, Michael O'Mahony, Marie-Pierre David, Kurt Dobbelaere, Gary Dubin & Dominique Descamps. (2012) Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls. Journal of Adolescent Health 50:1, pages 38-46.
Crossref
Crossref
Stéphanie Longet, John T. Schiller, Martine Bobst, Patrice Jichlinski & Denise Nardelli-Haefliger. (2011) A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus Infection. Journal of Virology 85:24, pages 13253-13259.
Crossref
Crossref
Cosette M. Wheeler, Bryan M. Harvey, Michael E. Pichichero, Michael W. Simon, Stephen P. Combs, Mark M. Blatter, Gary S. Marshall, Grégory Catteau, Kurt Dobbelaere, Dominique Descamps, Gary Dubin & Anne Schuind. (2011) Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 Years of Age. Pediatric Infectious Disease Journal 30:12, pages e225-e234.
Crossref
Crossref
Channa E. Schmeink, Ruud L.M. Bekkers, Ann Josefsson, Jan H. Richardus, Katarina Berndtsson Blom, Marie-Pierre David, Kurt Dobbelaere & Dominique Descamps. (2011) Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls. Vaccine 29:49, pages 9276-9283.
Crossref
Crossref
Rolando Herrero, Sholom Wacholder, Ana C. Rodríguez, Diane Solomon, Paula González, Aimee R. Kreimer, Carolina Porras, John Schussler, Silvia Jiménez, Mark E. Sherman, Wim Quint, John T. Schiller, Douglas R. Lowy, Mark Schiffman & Allan Hildesheim. (2011) Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. Cancer Discovery 1:5, pages 408-419.
Crossref
Crossref
Sarah E. Coseo, Carolina Porras, Lori E. Dodd, Allan Hildesheim, Ana Cecilia Rodriguez, Mark Schiffman, Rolando Herrero, Sholom Wacholder, Paula Gonzalez, Mark E. Sherman, Silvia Jimenez, Diane Solomon, Catherine Bougelet, Leen-Jan van Doorn, Wim Quint & Mahboobeh Safaeian. (2011) Evaluation of the Polyclonal ELISA HPV Serology Assay as a Biomarker for Human Papillomavirus Exposure. Sexually Transmitted Diseases 38:10, pages 976-982.
Crossref
Crossref
Aimée R Kreimer, Paula González, Hormuzd A Katki, Carolina Porras, Mark Schiffman, Ana Cecilia Rodriguez, Diane Solomon, Silvia Jiménez, John T Schiller, Douglas R Lowy, Leen-Jan van Doorn, Linda Struijk, Wim Quint, Sabrina Chen, Sholom Wacholder, Allan Hildesheim & Rolando Herrero. (2011) Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. The Lancet Oncology 12:9, pages 862-870.
Crossref
Crossref
Nathalie Garçon, Lawrence Segal, Fernanda Tavares & Marcelle Van Mechelen. (2011) The safety evaluation of adjuvants during vaccine development: The AS04 experience. Vaccine 29:27, pages 4453-4459.
Crossref
Crossref
Mel Krajden, Darrel Cook, Amanda Yu, Ron Chow, Wendy Mei, Shelly McNeil, Deborah Money, Marc Dionne, Karuna P. Karunakaran, Joel M. Palefsky, Simon Dobson, Gina Ogilvie & Martin Petric. (2011) Human Papillomavirus 16 (HPV 16) and HPV 18 Antibody Responses Measured by Pseudovirus Neutralization and Competitive Luminex Assays in a Two- versus Three-Dose HPV Vaccine Trial. Clinical and Vaccine Immunology 18:3, pages 418-423.
Crossref
Crossref
Susanna Esposito, Victoria Birlutiu, Pavol Jarcuska, Antonio Perino, Sorin Claudiu Man, Radu Vladareanu, Dorothée Meric, Kurt Dobbelaere, Florence Thomas & Dominique Descamps. (2011) Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 Years. Pediatric Infectious Disease Journal 30:3, pages e49-e55.
Crossref
Crossref
Seung Cheol KimYong Sang SongYoung-Tae KimYoung Tak KimKi-Sung RyuBhavyashree GunapalaiahDan BiHans L BockJong-Sup Park. (2011) Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women. Journal of Gynecologic Oncology 22:2, pages 67.
Crossref
Crossref
Carolina Porras, Christina Bennett, Mahboobeh Safaeian, Sarah Coseo, Ana Cecilia Rodríguez, Paula González, Martha Hutchinson, Silvia Jiménez, Mark E Sherman, Sholom Wacholder, Diane Solomon, Leen-Jan van Doorn, Catherine Bougelet, Wim Quint, Mark Schiffman, Rolando Herrero & Allan Hildesheim. (2010) Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infectious Diseases 10:1.
Crossref
Crossref
M. Safaeian, C. Porras, M. Schiffman, A. C. Rodriguez, S. Wacholder, P. Gonzalez, W. Quint, L.-J. van Doorn, M. E. Sherman, V. Xhenseval, R. Herrero & A. Hildesheim. (2010) Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections. JNCI Journal of the National Cancer Institute 102:21, pages 1653-1662.
Crossref
Crossref
Sarah Coseo, Carolina Porras, Allan Hildesheim, Ana Cecilia Rodriguez, Mark Schiffman, Rolando Herrero, Sholom Wacholder, Paula Gonzalez, Sophia S. Wang, Mark E. Sherman, Silvia Jimenez, Diane Solomon, Catherine Bougelet, Leen-Jan van Doorn, Wim Quint & Mahboobeh Safaeian. (2010) Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica. Sexually Transmitted Diseases 37:11, pages 706-714.
Crossref
Crossref
N. De Carvalho, J. Teixeira, C.M. Roteli-Martins, P. Naud, P. De Borba, T. Zahaf, N. Sanchez & A. Schuind. (2010) Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 28:38, pages 6247-6255.
Crossref
Crossref
Joseph G. Dauner, Yuanji Pan, Allan Hildesheim, Clayton Harro & Ligia A. Pinto. (2010) Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 28:33, pages 5407-5413.
Crossref
Crossref
David Opalka, Katie Matys, Paul Bojczuk, Tina Green, Richard Gesser, Alfred Saah, Richard Haupt, Frank Dutko & Mark T. Esser. (2010) Multiplexed Serologic Assay for Nine Anogenital Human Papillomavirus Types. Clinical and Vaccine Immunology 17:5, pages 818-827.
Crossref
Crossref
ND ChristensenCE Bounds. (2010) Cross-protective responses to human papillomavirus infection. Future Virology 5:2, pages 163-174.
Crossref
Crossref
J. Cortés, F. Martinón, G. Ferret, E. García, J.M. Ramón y Cajal, R. Garrido, P. Miranda, D. Dexeus, A. Gil & R. Cisterna. (2010) Vacunas frente al virus del papiloma humano: actualización. Clínica e Investigación en Ginecología y Obstetricia 37:2, pages 63-74.
Crossref
Crossref
José Garcia-Sicilia, Tino F. Schwarz, Alfonso Carmona, Klaus Peters, Jean-Elie Malkin, Phu M. Tran, Ulrich Behre, Enrique B. Iturbe, Gregory Catteau, Florence Thomas, Kurt Dobbelaere, Dominique Descamps & Gary Dubin. (2010) Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis–inactivated Poliovirus Vaccine to Girls and Young Women. Journal of Adolescent Health 46:2, pages 142-151.
Crossref
Crossref
Mel Krajden, Karuna Karunakaran, Stacy So, Joel M. Palefsky, Rachna Sharma, Darrel Cook, Amanda Yu, Ron Chow, Simon Dobson, Gina S. Ogilvie & Martin Petric. (2009) Prevalence of Human Papillomavirus 16 and 18 Neutralizing Antibodies in Prenatal Women in British Columbia. Clinical and Vaccine Immunology 16:12, pages 1840-1843.
Crossref
Crossref
Diane M Harper. (2009) Current prophylactic HPV vaccines and gynecologic premalignancies. Current Opinion in Obstetrics & Gynecology 21:6, pages 457-464.
Crossref
Crossref
Diana V. Pastrana, Yanis L. Tolstov, Jürgen C. Becker, Patrick S. Moore, Yuan Chang & Christopher B. Buck. (2009) Quantitation of Human Seroresponsiveness to Merkel Cell Polyomavirus. PLoS Pathogens 5:9, pages e1000578.
Crossref
Crossref
Eduardo Lazcano-Ponce & Betania Allen-Leigh. (2009) Innovation in Cervical Cancer Prevention and Control in Mexico. Archives of Medical Research 40:6, pages 486-492.
Crossref
Crossref
J Paavonen, P Naud, J Salmerón, CM Wheeler, S-N Chow, D Apter, H Kitchener, X Castellsague, JC Teixeira, SR Skinner, J Hedrick, U Jaisamrarn, G Limson, S Garland, A Szarewski, B Romanowski, FY Aoki, TF Schwarz, WAJ Poppe, FX Bosch, D Jenkins, K Hardt, T Zahaf, D Descamps, F Struyf, M Lehtinen & G Dubin. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet 374:9686, pages 301-314.
Crossref
Crossref